Alok Industries Q2 FY27 results: board meet Oct 15, 2026

Board meeting set for October 15

Alok Industries Ltd has informed the BSE that its Board of Directors will meet on October 15, 2026. The agenda is to consider and approve the standalone and consolidated unaudited financial results. These results will cover the quarter as well as the half-year ended September 30, 2026. For listed companies, board-level approval is a key step before results become generally available to the market. The timing also aligns with the company’s regular quarterly reporting cycle visible in its corporate action calendar. Investors typically track such intimations because they set expectations on when official financial numbers will be published. The filing is part of routine regulatory communication rather than an operational update. Still, the Q2 and H1 numbers can matter because they provide a more complete picture than a single quarter.

What the BSE intimation says

The company’s intimation states that the meeting is scheduled on 15/10/2026. It adds that the board will, among other matters, consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026. The filing is positioned as information “for your information and records,” reflecting standard exchange disclosure language. A similar “Board Meeting Intimation” entry is also shown as released on October 8, 2026. The disclosures, as presented, focus on process and timing rather than providing preliminary numbers. There is no guidance mentioned in the text shared, and no commentary on operations is included. The key takeaway for the market is the confirmation of the results date. That date also helps frame the trading window closure period described in a separate disclosure.

Trading window closure linked to the results

A separate announcement titled “Closure of Trading Window” was released on September 30, 2026 at 03:55 pm, sourced to BSE. It states that the trading window close period will commence from October 1, 2026. The closure will end 48 hours after the financial results for the second quarter ending September 30, 2026 become generally available information. The disclosure references the company’s internal code to regulate, monitor and report trading by directors, promoters, designated persons and specified connected persons. Trading window closures are a common compliance measure around price-sensitive announcements. The dates matter because they indicate when insiders and connected persons are restricted from trading under the code. For outside investors, this disclosure is mainly a compliance signal rather than a price indicator. It also reinforces that the company is following a structured timeline around Q2 reporting.

Where this sits in Alok Industries’ corporate action calendar

The corporate actions section lists multiple results-related milestones across 2026. It shows quarterly results on October 15, 2026 and July 16, 2026, and audited results on April 16, 2026. It also lists quarterly results on January 15, 2026 and October 16, 2025. A separate corporate actions entry also shows a board meeting purpose of “Quarterly Results,” announced around early October 2026. Together, these items suggest a steady quarterly reporting rhythm. The October 15 meeting therefore appears to be the scheduled forum to approve Q2 FY2026-27 numbers and H1 FY2026-27 numbers. The timeline also matters because the company had already approved unaudited results for the quarter ended June 30, 2026 at a board meeting outcome announced around July 16, 2026. In practice, the Q2 meeting completes the first-half reporting for FY2026-27.

Latest disclosed quarterly snapshot: Q1 FY2026-27

In the financial highlights provided, Alok Industries reported revenue of ₹998.24 crore for Q1 FY2026-27. The same highlights show profit at ₹-138.25 crore for that quarter, indicating a loss. In the “Insights” table, “Total Income” for the June 2026 quarter is also shown at ₹998.24 crore. These figures provide the most recent quarterly reference point ahead of the September 2026 quarter and half-year update. The board meeting outcome text for the quarter ended June 30, 2026 states that the board approved unaudited financial results (consolidated and standalone) along with independent auditors’ review reports, as recommended by the audit committee. That sequence is typical: audit committee review, board approval, and then disclosure. The October 15 meeting is expected to follow a similar approval process for the September 2026 period, based on the agenda described.

Full-year FY2026 numbers reported in the update

The text provided also includes full-year FY2026 results: revenue of ₹3,790 crore (stated as ₹37.9b) and a net loss of ₹744 crore (stated as ₹7.44b). It adds that revenue was up 2.2% versus FY2025, and net loss narrowed 8.9% versus FY2025. On per-share performance, it mentions a FY2026 loss of ₹1.50 per share, improved from a ₹1.64 loss in FY2025. These are historical context points rather than Q2 indicators, but they help readers understand the broader direction of annual performance. They also show that while losses continued in FY2026, the magnitude improved compared with the prior year based on the figures shared. Any comparison to FY2026 in upcoming quarters will therefore be watched in relation to these baselines. However, the October 15 board meeting intimation itself does not provide Q2 or H1 numbers.

Key facts at a glance

Regulatory filings context in 2026

The update notes that 112 regulatory filings released by Alok Industries Ltd in 2026 were sourced directly from the official regulator. Within the excerpts shown, items include a “Board Meeting — Financial Results Report Publication Announcement” released on October 8, 2026 and a “Trading Window Regulatory Filings” entry dated September 30, 2026. The presence of repeated board meeting intimations and outcomes in the text reflects the standard disclosure trail: intimation before the meeting and outcome or publication after decisions are made. The July 2026 references indicate that Q1 approvals were already completed earlier in the year. This pattern matters because it indicates the company’s disclosures are being routed through formal exchange channels. For investors following the stock, exchange timestamps and document types often serve as the official record for results and compliance-related events.

What investors will watch on October 15

The October 15 meeting is important because it is set to approve both quarterly and half-year unaudited numbers up to September 30, 2026. Half-year reporting provides a wider window into performance than a single quarter, especially for businesses where quarterly trends can vary. The market will look for the standalone and consolidated figures once they are released and become generally available information. The trading window disclosure also suggests that management expects the results to be price sensitive enough to warrant restrictions under the internal code. Separately, the most recent disclosed quarterly snapshot shows revenue near ₹1,000 crore and a loss in Q1 FY2026-27, which sets a reference point for readers tracking sequential performance. But the board meeting intimation does not include management commentary, guidance, or operational details. The next concrete update, based on the text shared, will be the approved unaudited results after the board meeting.

Conclusion

Alok Industries has scheduled its board meeting for October 15, 2026 to approve unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company has also disclosed a trading window closure starting October 1, 2026, ending 48 hours after results become generally available information. In the latest disclosed quarter (Q1 FY2026-27), revenue was ₹998.24 crore and profit was ₹-138.25 crore. On an annual basis, FY2026 revenue was ₹3,790 crore with a net loss of ₹744 crore, and the loss per share improved to ₹1.50 from ₹1.64 in FY2025. The next scheduled step is the board’s consideration and approval on October 15, followed by the exchange disclosure of the approved results.